BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200316
DTEND;VALUE=DATE:20200318
DTSTAMP:20260515T064526
CREATED:20191101T085034Z
LAST-MODIFIED:20191101T085034Z
UID:23143-1584316800-1584489599@www.pharmajournalist.com
SUMMARY:AI in Drug Discovery Conference 2020
DESCRIPTION:Leveraging machine learning – discovery to the next level! \nSMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March 2020. \nAI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR\, AI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nThe presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with AI-enabled platforms using machine learning and deep learning\, neural networks and natural language processing. However\, there is a long journey ahead of optimizing AI-human connections and understanding the full potential of AI-enabled tools and platforms. \n \nBENEFITS OF ATTENDING: \n\nListen to case studies form industry leader pharmaceutical and biotechnology that have already incorporated AI into their work\nExplore how Deep Learning Methods can be leveraged for compound screening\, de novo design\, multiparameter optimization/ ADME toxicity property predictions\, chemical synthesis route predictions\nDiscover strategies for overcoming data-related challenges such as lack of consistent and quality data at the heart of AI and strategies for improving data access\nDefine unique discovery approaches such as fragment-based drug discovery and network-driven drug discovery\n\nJoin us at SMi’s inaugural AI in Drug Discovery 2020 Conference and explore the latest AI-enabled approaches for lead compound screening\, multi parameter optimization\, disease modelling\, drug synthesis and design. \nTo register please visit: www.AI-indrugdiscovery.com/pharmajwl \nPLUS\, one interactive half-day post-conference workshop \nPractical application of predictive properties in drug design\, Workshop Leader: Robert Young\, Blue Burgundy Ltd. \nEarly-Bird Rates \n\nBOOK BY 29TH NOVEMBER AND SAVE £400\nBOOK BY 13TH DECEMBER AND SAVE £200\nBOOK BY 31ST JANUARY AND SAVE £100\n\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMiDrugdiscovery\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/ai-in-drug-discovery-conference-2020/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
END:VCALENDAR